// App-Quantinova.ai

: Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC).

Researchers

Presenter

  • Alexandre Xu-Vuillard

Principal Investigators

  • Anne Jouinot

  • Thomas Pudlarz

  • Benoit Blanchet

  • Olivier Huillard

  • Charlotte Joly

  • Christophe Tournigand

  • Stephane Oudard

  • Jacques Medioni

  • Yann-Alexandre Vano

Medical Centers

  • Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France

  • Department of Medical Oncology, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, France

  • Department of Medical Oncology, Hôpital Henri-Mondor, AP-HP - Université de Paris Est, Créteil, France

  • AP-HP, Hôpital Cochin Port-Royal, Department of Medical Oncology, ARIANE, Institut du Cancer Paris CARPEM, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved